...7891011...203040...


GMP Cell Banking Services Market: Subsequent demand for stem cell therapies would provide a major boost to the market – BioSpace

Global GMP Cell Banking Services Market: Overview

A burgeoning pharmaceutical industry hard-pressed to find treatments and cures for various chronic and other ailments has given rise to the concept of cell banking. With limited capacity to store cells required for research in the field of regenerative medicines, somatic cell therapy, gene therapy, and tissue-engineered products they are increasingly outsourcing it to other entities specializing in it.

Read Report Overview - http://www.transparencymarketresearch.com/gmp-cell-banking-services-market.html

GMP basically stands for Good Manufacturing Practice. A recent report on GMP cell banking services finds that the market is set to rise in the near term with the capacity constraints being faced by the pharmaceutical manufacturing companies and medical research institutes.

An upcoming report on the global GMP cell banking services market by Transparency Market Research attempts to examine in depth the factors molding it. It studies both the market specific factors and macro fundamentals stoking or hindering market growth. The report also segments the GMP cell banking services market based on different parameters such as applications and geography. It then deep dives into each sector to understand which ones hold out maximum promise. The report also tries to figure out the current and future size of the market with respect to revenue generation.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=50559

Global GMP Cell Banking Services Market: Key Trends

A cell bank comprises of a storage facility for cells extracted from different body fluids and organ tissue so that they can be used in the future. Stored cells contain detailed characterization of the cell line thereby decreasing chances of cross contamination. And GMP cell banking services consists of outsourcing gathering, storing, characterization, and testing facilities of cell lines, tissues, and cells. The report predicts that the rising popularity and subsequent demand for stem cell therapies would provide a major boost to the global GMP cell banking services market.

As per the TMR report, the global GMP cell banking services market is also being boosted by the development of cutting-edge preservation technologies and surging research in cell line development. However, complexity of the entire procedure and inconsistent demand is dampening market growth to an extent.

Request for Analysis of COVID19 Impact on GMP Cell Banking Services Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=50559

Depending upon the cell type, the global GMP cell banking services market can be segmented into microbial, mammalian, yeast, insect, stem cell, and avian, among others. Among them, the segment of mammalian currently has a significant share in the market. It generates most of the revenue and would probably rise at a healthy clip in the years to come. Meanwhile, the microbial segment is predicted to emerge as the most attractive in the upcoming years.

Global GMP Cell Banking Services Market: Regional Outlook

The global GMP cell banking services market is spread across North America, Europe, Asia Pacific, and the Middle East and Africa. North America, among them, is considered one of the attractive GMP cell banking services market with the mammalian cell type segment generating most of the revenue. The segment has also been generating substantial revenue in the Asia Pacific GMO cell banking services market. In fact, the Asia Pacific market is seeing solid rise because of the shift of research and development activities in the region from North America and Europe.

Pre Book GMP Cell Banking Services Market Research - https://www.transparencymarketresearch.com/checkout.php?rep_id=50559&ltype=S

Global GMP Cell Banking Services Market: Competitive Dynamics

The global GMP cell banking services market is fragmented in nature. This is because of the presence of several companies offering a range of services in it. This also limits their global outreach and localizes competition. Some the key players among them profiled in the report include WuXi AppTec, Eurofins Scientific, Charles River Laboratories International, Inc., Lonza Group Ltd., and SGS Ltd.

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Read the original here:

GMP Cell Banking Services Market: Subsequent demand for stem cell therapies would provide a major boost to the market - BioSpace

Notch Therapeutics Appoints David Main as President and Chief Executive Officer to Advance the Company’s Novel Gene-Edited, iPSC-Derived Immune Cell…

TORONTO, July 20, 2020 /PRNewswire/ --Notch Therapeutics Inc., a biotechnology company creating universally compatible, off-the-shelf T cell therapies for cancer and immune disorders from renewable stem cell sources, is pleased to announce the appointment of David Main as President and Chief Executive Officer.

Notch is applying its scalable Engineered Thymic Niche (ETN) technology platform to develop homogeneous and universally compatible, stem cell-derived T cell therapies. To date, Notch has assembled a world-class scientific team and built a fully integrated, tightly controlled platform for generating and editing immune cells from clonal stem cells to enable development of a broad range of T cell therapeutics. Notch has also entered into a partnership with Allogene Therapeutics (NASDAQ: ALLO) to apply Notch's proprietary ETN platform to develop CAR-targeted, induced pluripotent stem cell (iPSC)-derived, off-the-shelf T cell or natural killer (NK) cell therapies for hematologic cancer indications.

"We have a clear goal at Notch: To create universally compatible, safe, and effective immunotherapies with the capability to treat thousands of patients from a single manufacturing run," said David Main. "The company has an internationally recognized team, a groundbreaking technology positioned to redefine and expand the clinical and commercial potential of cell therapy, and has already attracted a leading corporate partner. This is an exciting time to join and lead the company, which is now strongly positioned to advance our own pipeline of products as we also pursue additional partnering opportunities."

"We have spent the past year building a leading company developing next-generation, off-the-shelf immunotherapies driven by outstanding science and focused execution," said Ulrik Nielsen, Ph.D., Chairman of Notch. "David provides Notch with a proven industry leader and strategic thinker who has extensive experience driving and financing biotech innovation from early-stage research through commercial readiness. We are excited to bring in such outstanding leadership that is ideally suited to lead the company as it continues to advance its new class of off-the-shelf T cell therapy products."

Mr. Main is a highly experienced biopharmaceutical executive who brings to Notch more than 30 years of industry leadership experience with a strong track record of value creation and company growth. Most recently, as co-founder, Chairman, and CEO of Aquinox Pharmaceuticals, Mr. Main oversaw the advancement of the company's lead product from target validation through Phase 3 clinical trials. He also led the transition of Aquinox from a private to a NASDAQ-listed public company with approximately $300 million raised in equity capital and then completed the successful merger of Aquinox with Neoleukin Therapeutics. Prior to his leadership of Aquinox, Mr. Main served as President and CEO of INEX Pharmaceuticals and as a Vice President of QLT.

About Notch Therapeutics (www.notchtx.com)Notch is an immune cell therapy company creating universally compatible, allogeneic (off-the-shelf) T cell therapies for the treatment of cancer and immune disorders. Notch's technology platform uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and has the potential to deliver safer, consistently manufactured and more cost-effective cell immunotherapies to patients. At the core of Notch's technology is the synthetic Engineered Thymic Niche (ETN) platform, which precisely controls the expansion and differentiation of stem cells in a process suitable for large-scale manufacturing, delivering fully defined, consistent, feeder-free and serum-free T cells that can be genetically tailored for any T cell-based immunotherapeutic application. This technology was invented in the laboratories of Juan-Carlos Ziga-Pflcker, Ph.D. at Sunnybrook Research Institute and Peter Zandstra, Ph.D., FRSC at the University of Toronto. Notch was founded by these two institutions, in conjunction with MaRS Innovation (now Toronto Innovation Acceleration Partners) and the Centre for Commercialization of Regenerative Medicine (CCRM) in Toronto.

Contact:Mary MoynihanM2Friend Biocommunications802-951-9600[emailprotected]

SOURCE Notch Therapeutics

Notch Therapeutics

Read more:

Notch Therapeutics Appoints David Main as President and Chief Executive Officer to Advance the Company's Novel Gene-Edited, iPSC-Derived Immune Cell...

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis & Technological Innovation – Jewish Life News

Data Bridge Market Research has recently published the Global research Report TitledAutologous Stem Cell and Non-Stem Cell Based Therapies Market. The study provides an overview of current statistics and future predictions of the Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market.The study highlights a detailed assessment of the Market and displays market sizing trends by revenue & volume (if applicable), current growth factors, expert opinions, facts, and industry validated market development data.

Order a Free Sample Copy of thisAutologous Stem Cell and Non-Stem Cell Based Therapies Market Report:https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Autologous Stem Cell and Non-Stem Cell Based Therapies market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market in each region. Various methodological tools are used to analyze the growth of the worldwide Autologous Stem Cell and Non-Stem Cell Based Therapies market.

List of Companies Profiled in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report are:

Takeda Pharmaceutical Company Limited, Cytori Therapeutics Inc., General Electric Spiegelberg GmbH & Co. KG ., Medtronic, Natus Medical Incorporated., Integra LifeSciences Corporation, RAUMEDIC AG, Abbott., Endotronix, Inc. among others.

Major Regions as Follows:

North America

Europe

Asia-Pacific

South America

Middle East and Africa

Key Pointers Covered in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trendsand Forecast to 2026

A complete value chain of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market is presented in the research report. It is associated with the review of the downstream and upstream components of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market. The market is spliton the basis of the categories of products and clientapplication segments. The market analysis demonstrates the expansion of each segment of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market. The research report assists the user in taking a decisive step on the way tobe a milestone ingrowingandexpandingtheirorganizationsinside theworldwideAutologous Stem Cell and Non-Stem Cell Based Therapies market.

How Does This Market Insights Help?

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart):https://www.databridgemarketresearch.com/toc/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

The report highlights current and future market trends and carries out an analysis of the effect of buyers, substitutes, new entrants, competitors, and suppliers on the market. The key topics that have been explained in this Autologous Stem Cell and Non-Stem Cell Based Therapies market report include market definition, market segmentation, key developments, competitive analysis and research methodology.

Why choose us:

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

In conclusion, the Autologous Stem Cell and Non-Stem Cell Based Therapies Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report Give information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability inspection and venture return investigation.

To Get the Short-Term and Long-Term Impact of COVID-19 on this Market:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

Go here to see the original:

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis & Technological Innovation - Jewish Life News

Current Trend: Global Covid-19 impact on Cancer Stem Cell Therapy Market 2020 Size, Growth Opportunities, Research Analysis and Forecast to 2025 |…

Trending Cancer Stem Cell Therapy Market 2020: COVID-19 Outbreak Impact Analysis

Chicago, United States ,The report entitled Global Cancer Stem Cell Therapy Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 released byReport Hive Researchcomprises an assessment of the market which provides the real-time market scenario and its projections during 2020 to 2025 time-period. The report offers an understanding of the demographic changes that took place in recent years. The report presents an analysis of market size, share, growth, trends, statistical and comprehensive facts of the global Cancer Stem Cell Therapy market. This research study presents informative information and in-depth evaluation of the market and its segments based totally on technology, geography, region, and applications.

The report highlights several significant features of the global Cancer Stem Cell Therapy market encompassing competitive landscape, segmentation analysis, and industry environment. It shows the scope of the market and a brief overview of the definition and description of the product or service. The potential factors that can bring the market to the upward direction have been mentioned in the report. With this report, companies, as well as individuals interested in this report, will get proven valuable guidelines and direction so that they consolidate their position in the market.The report assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the Cancer Stem Cell Therapyindustry. Growth of the overall Cancer Stem Cell Therapymarket has also been forecasted for the period 2020-2025, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

>>>>To know How COVID-19 Pandemic Will Impact This Cancer Stem Cell Therapy Market| Download PDF Sample copy of the Report

>>>>The study encompasses profiles of major companies operating in the global Cancer Stem Cell Therapy Market. Key players profiled in the report include: AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems

Drivers And Risks:The report covers the basic dynamics of the global Cancer Stem Cell Therapy market. It scrutinizes several data and figures, and numerous volume trends. A number of potential growth factors, risks, restraints, challenges, market developments, opportunities, strengths, and weaknesses have been highlighted. Another factor affecting market growth has also been included in the report.

Analysis of Global Cancer Stem Cell Therapy Market By Type: Autologous Stem Cell TransplantsAllogeneic Stem Cell TransplantsSyngeneic Stem Cell TransplantsOthers

Analysis of Global Cancer Stem Cell Therapy Market By Application: HospitalClinicMedical Research InstitutionOthers

Regional Analysis:The report comprises of regional development status, covering all the major regions of the world. This regional status shows the size (in terms of value and volume), and price data for the global Cancer Stem Cell Therapy market. The development of the industry is assessed with information on the current status of the industry in various regions. Data type assessed concerning various regions includes capacity, production, market share, price, revenue, cost, gross, gross margin, growth rate, consumption, import, export, etc.

Regional coverage:North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Some Main Reasons For Purchasing This Report:

Readers of this report will receive in-depth knowledge about the market.

Updated statistics offered on the global Cancer Stem Cell Therapy market report.

This report provides an insight into the market that will help you boost your companys business and sales activities.

It will help you to find prospective partners and suppliers.

It will assist and strengthen your companys decision-making processes.

NOTE: Our team is studying Covid-19 impact analysis on various industry verticals and Country Level impact for a better analysis of markets and industries. The 2020 latest edition of this report is entitled to provide additional commentary on latest scenario, economic slowdown and COVID-19 impact on overall industry. Further it will also provide qualitative information about when industry could come back on track and what possible measures industry players are taking to deal with current situation.

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Cancer Stem Cell Therapy market.

Chapter 2: Evaluating the leading manufacturers of the global Cancer Stem Cell Therapy market which consists of its revenue, sales, and price of the products.

Chapter 3: the competitive nature among key manufacturers, with market share, revenue, and sales.

Chapter 4: Presenting global Cancer Stem Cell Therapy market by regions, market share and revenue and sales for the projected period.

Chapters 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

>>>>Get Full Customize report @ https://www.reporthive.com/request_customization/2360734

In this report, Leading players of the global Cancer Stem Cell Therapy Market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Cancer Stem Cell Therapy Market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Cancer Stem Cell Therapy Market. It also provides useful recommendations for new as well as established players of the global Cancer Stem Cell Therapy Market.

Get Free Sample Copy of this report: https://www.reporthive.com/request_sample/2360734

Why Go For Report Hive Research?

Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Get in Touch with Us :Report Hive Research500, North Michigan Avenue,Suite 6014,Chicago, IL 60611,United StatesWebsite: : https://www.reporthive.comEmail: [emailprotected]Phone:+1 312-604-7084

Read more:

Current Trend: Global Covid-19 impact on Cancer Stem Cell Therapy Market 2020 Size, Growth Opportunities, Research Analysis and Forecast to 2025 |...

New Research on Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020-2026 Industry Size, Share, Types, Regional Analysis, Manufacturers…

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market was estimated to be valued at USD XX million in 2018 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2020 to 2026. Increasing prevalence of chronic diseases and adaptation of advanced technology are driving the market growth. However high cost of the therapy might restraint the market growth

For Sample Copy of this Report @ https://www.orianresearch.com/request-sample/1131253

What You Can Expect From Our Report:

Autologous Stem Cell and Non-Stem Cell Based Therapies Industry report offers a comprehensive insight into the development policies and plans in addition to manufacturing processes and cost structures. On the basis of product, this report displays the cost structure, sales revenue, sales volume, gross margin, market share and growth rate.

Report Covers Market Segment by Manufacturers:

Report Covers Market Segment by Types:

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Industry 2020 Market Research Report is spread across 121 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Order Copy of this Report 2020 @ https://www.orianresearch.com/checkout/1131253

Report Covers Market Segment by Applications:

Key Benefits of the Report:

Target Audience:

Inquire more about Autologous Stem Cell and Non-Stem Cell Based Therapies Market report @ https://www.orianresearch.com/enquiry-before-buying/1131253

Research Methodology

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective like analyst report of investment banks. The secondary research forms the base of our study where we conducted extensive data mining, referring to verified data sources such as white papers government and regulatory published materials, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factor, investment, market dynamics including technical scenario, consumer behavior, and end use industry trends and dynamics, capacity Types, spending were taken into consideration.

We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the

Key Industry Participants (KIPs) which typically include:

Table of Content

1 Executive Summary

2 Methodology And Market Scope

3 Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Outlook

4 Autologous Stem Cell and Non-Stem Cell Based Therapies Market By End User

5 Autologous Stem Cell and Non-Stem Cell Based Therapies Market Type

6 Autologous Stem Cell and Non-Stem Cell Based Therapies Market Regional Outlook

7 Competitive Landscape

End of the report

Disclaimer

About Us

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (415) 830-3727 | UK: +44 020 8144-71-27

Email: [emailprotected]

More here:

New Research on Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020-2026 Industry Size, Share, Types, Regional Analysis, Manufacturers...

NK Cell Therapy and Stem Cell Therapy Market 2020-26, Research Report Covers Updated Data Considering Impact of Covid-19 on Share, Size and Future…

NK Cell Therapy and Stem Cell Therapy Market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global NK Cell Therapy and Stem Cell Therapy Market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2015-2026.

Report Overview: This report covers an analysis of the global NK Cell Therapy and Stem Cell Therapy Market for the forecast period 2020-2026. It unravels that the market is set to register steady growth rate in the coming years. The valuation of the global market is covered for facilitating a comparative study of the past and future data. It also offers a detailed segmental assessment of the market based on different parameters.

Leading Key Players:Chipscreen BiosciencesInnate Pharma SAOsiris TherapeuticsChiesi PharmaceuticalsMolmedJCR PharmaceuticalAltor BioScience CorporationAffimed NVTakeda PharmaceuticalPharmicellMedi-postNuVasiveAnterogen

This analysis includes a detailed share analysis of the key players. It also unveils the growth trajectories of the NK Cell Therapy and Stem Cell Therapy Market participants along with their current statuses and key developments. The growth strategies employed by these players are also assessed in the report and are prognosticated to facilitate study of the competitive landscape of the global Artificial Heart Valve Market.

Get Free Sample [emailprotected] https://www.algororeports.com/sample-request/nk-cell-therapy-and-stem-cell-therapy-market-research-report-trends-one-2940079?utm_source=3wnews&utm_medium=53

Drivers and Restraints: The factors that are supposed to lead the expansion of the global market are highlighted in the assessment. The market factors are assessed and analyzed to understand their impact on the growth curve. Similarly, the factors that are presumed to restrain the growth of the market are also studied in the report.

Regional Analysis: The regions covered for the evaluation of the global NK Cell Therapy and Stem Cell Therapy Market are

North America (Covered in Chapter 6 and 13)United StatesCanadaMexicoEurope (Covered in Chapter 7 and 13)GermanyUKFranceItalySpainRussiaOthersAsia-Pacific (Covered in Chapter 8 and 13)ChinaJapanSouth KoreaAustraliaIndiaSoutheast AsiaOthersMiddle East and Africa (Covered in Chapter 9 and 13)Saudi ArabiaUAEEgyptNigeriaSouth AfricaOthersSouth America (Covered in Chapter 10 and 13)BrazilArgentinaColumbiaChileOthers

The analysis of these regional segment is followed by a country-level analysis of each for every region. A comparative study of the segments is offered with the inclusion of valuation for every segment on both country and regional level.

Method of Research: The assessment leverages advanced and robust methodologies to provide fact-based actionable insight into the market. Key market divergences are analyzed in the report for deriving accurate information regarding the growth trajectory of the market. These market divergences identified in the research process are current status of the market, ongoing industry trends, past data, latest developments, etc. Cutting-edge data analytical tools are employed for the filtration, validation, and authentication of data collected from primary and secondary research sources. The inputs are collected from credible sources, including but not limited to, paid database services, interviews with stakeholders across the value chain (MDs, CEOs, VPs,etc.), SEC filings, surveys, and whitepaper references among others. Zero deviation from facts is ensured with the utilization of a multi-layer verification process. It also assures adherence to the highest standards of data mapping and value extrapolation. Top-down and bottom-up approaches are executed to authenticate the accuracy of the quantitative data provided in the report.

CONTENTS

ENQUIREY TO BUY REPORT@ https://www.algororeports.com/enquiry/nk-cell-therapy-and-stem-cell-therapy-market-research-report-trends-one-2940079?utm_source=3wnews&utm_medium=53

About Us:

AlgoroReportsis one of the most significant database of online market researches and intelligence reports and services. The online portal for marketing research deals with access to global market data and assists in providing expert insights and exposure on global companies, industries, products and trends. AlgoroReports Consists of a highly motivated team of young and experienced individual focused on providing clients expert information they need.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

Website: https://www.algororeports.com/

Ph: +1-352-353-0818 (US)

See the original post:

NK Cell Therapy and Stem Cell Therapy Market 2020-26, Research Report Covers Updated Data Considering Impact of Covid-19 on Share, Size and Future...

Stem Cell Therapy Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2020 – Jewish Life News

New Study on the Global Stem Cell Therapy Market by PMR

PMR recently published a market study that sheds light on the growth prospects of the global Stem Cell Therapy market during the forecast period (20XX-20XX). In addition, a methodical and systematic approach adopted by the analysts while curating the market study ensures that the presented study adds value to the business of our customers. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Stem Cell Therapy market.

As per the report, the global Stem Cell Therapy market is expected to grow at a CAGR of ~XX% during the stipulated timeframe owing to a range of factors including, favorable government policies, and growing awareness related to the Stem Cell Therapy , surge in research and development and more.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/3253

Resourceful insights enclosed in the report:

Competitive Outlook

The competitive outlook section provides valuable information related to the different companies operating in the current Stem Cell Therapy market landscape. The market share, product portfolio, pricing strategy, sales and distribution channels of each company is discussed in the report.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/3253

Regional Assessment

The presented market study touches upon the market scenario in different regions and provides a deep understanding of the influence of micro and macro-economic factors on the prospects of the market in each region.

Some of the major companies operating in the global stem cell therapy market are Mesoblast Ltd., Celgene Corporation, Aastrom Biosciences, Inc. and StemCells, Inc.

Key points covered in the report

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/3253

The market report addresses the following queries related to the Stem Cell Therapy market:

Read the rest here:

Stem Cell Therapy Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2020 - Jewish Life News

U of T spin-off Empirica Therapeutics acquired by US firm – News@UofT

Empirica Therapeutics, a startup co-founded by Donnelly Centre investigatorJason Moffathas beenacquired by Century Therapeutics, a U.S. based company developing off-the-shelf cell therapy products for cancer.

Century will develop Empiricas proof-of-principle treatment for glioblastoma, an aggressive form of brain cancer, into therapy that can be tested on patients.

Moffat co-founded Empirica in 2018 with Dr. Sheila Singh, professor in the department of surgery at McMaster University, to leverage their combined expertise in cell engineering, functional genomics and brain tumour modelling. The teams recently demonstrated the potential of CAR-T cell therapy, in which immune cells are instructed to kill tumour cells, for the treatment of glioblastoma in preclinical models, as published in a May 2020Cell Stem Cellpaper.

Recent advances in immunotherapy have offered hope to patients with previously untreatable cancers, says Moffat, a professor of molecular genetics at U of T and the Canada Research Chair in Functional Genomics of Cancer who served as Empiricas chief scientific officer. We hope that our approach of specifically targeting glioblastoma cells with CAR-T therapy will give the patients a better quality of life and increase their chances of survival.

Philadelphia-based Century Therapeutics will further develop this type of treatment for patients. Backed by Bayer, Fujifilm, and Versant Ventures, the company specializes in developing cell therapies from induced pluripotent stem cells (iPSCs) that have been genetically engineered to avoid immune rejection. Century is working to harness the power of stem cells to develop curative cell therapy products for cancer that overcome the limitations of first-generation cell therapies. The companys CEO, Lalo Flores, acknowledged Empiricas deep expertise and unique capabilities that will accelerate their efforts to develop iPSC derived immune effector cell products designed to treat brain cancer.

Chimeric antigen receptor T cell (CAR-T) therapy involves genetically engineering a patients immune T cells to target and bind to a specific protein present on cancer cells directly and eliminate them. Centurys technology skirts the need to collect patients own immune cells thanks to its ability to manufacture off-the-shelf T cells that can be implanted without rejection.

Our team is excited to become part of Century Therapeutics, whose iPSC-derived allogeneic cell therapy platform is creating promising treatments for patients who need them most, says Dr. Singh, who is also a Canada Research Chair in Human Cancer Stem Cell Biology and served as Empiricas chief executive officer.

Now known as Century Therapeutics Canada, the new subsidiary will be based at McMaster Innovation Park.

Empiricas first CAR-T program was focused on a protein called CD133, which was the first brain tumor initiating cell marker discovered by Singh while a PhD student at the University of Toronto. Subsequent work by both the Singh and Moffat groups led to a deeper functional understanding of CD133 and an antibody that proved useful for marking cells for therapy.

When used in mice with human glioblastoma, CD133-targetting CAR-T therapy was considered a success due to reduced tumor burden and improved survival. These pre-clinical results were partly supported by a Terry Fox Research Institute New Frontiers Program Project Grant awarded to a multidisciplinary team of scientists including Singh and Moffat.

Glioblastoma is the most common and aggressive form of brain cancer owing to tumour heterogeneity at the molecular level and its ability to evolve into new forms that resist therapy. Standard treatment involves surgery, radiation and chemotherapy but most patients relapse within seven to nine months, while median survival between diagnosis and death has not extended beyond 16-20 months over the past decade.

CAR-T will be delivered in recurrent glioblastoma patients after Moffat and Singhs teams found that a population of CD133 positive glioblastoma cells remain following initial treatment.

If we can hit those cells at minimal disease, we should buy the patient more time, says Moffat. And hopefully well find a way to figure out how to combine multiple CAR-Ts; for example, by combining CD133 and other targets to potentially even cure the disease.

Empirica Therapeutics was supported by investments from U of Ts strategic partners, the Centre for Commercialization of Antibodies and Biologics and the Centre for Commercialization of Regenerative Medicine.

We are proud to have been involved with the launch and growth of Empirica, stated Rob Verhagen, former CEO of CCAB. The outcome with Century marks another stride in building a productive life science industry at U of T and McMaster and we look forward to seeing this valuable research benefiting patients in the future. The startup was also supported by the McMaster Industry Liaison Office and the Ontario Bioscience Innovation Organization through important connections to relevant business networks and partners.

See the rest here:

U of T spin-off Empirica Therapeutics acquired by US firm - News@UofT

Rheumatoid Arthritis Stem Cell Therapy Market Share, Growth by Top Company, Region, Applications, Drivers, Trends & Forecast to 2018 to 2028 – 3rd…

Latest Study on the Global Rheumatoid Arthritis Stem Cell Therapy Market

The recently published report by Transparency Market Research on the global Rheumatoid Arthritis Stem Cell Therapy market offers resourceful insights pertaining to the future prospects of the Rheumatoid Arthritis Stem Cell Therapy market. The underlying trends, growth opportunities, impeding factors, and glaring market drivers are thoroughly studied in the presented report.

As per the report, the global Rheumatoid Arthritis Stem Cell Therapy market is projected to grow at a CAGR of ~XX% and exceed the value of ~US$ towards the end of 2029. Moreover, an in-depth analysis of the micro and macro-economic factors that are anticipated to influence the trajectory of the Rheumatoid Arthritis Stem Cell Therapy market during the forecast period (2019-2029) is included in the report.

Critical Insights Related to the Rheumatoid Arthritis Stem Cell Therapy Market in the Report:

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1001

Rheumatoid Arthritis Stem Cell Therapy Market Segments

Competitive landscape

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1001

Important queries related to the Rheumatoid Arthritis Stem Cell Therapy market addressed in the report:

Why Choose Rheumatoid Arthritis Stem Cell Therapy Market Report?

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1001

Excerpt from:

Rheumatoid Arthritis Stem Cell Therapy Market Share, Growth by Top Company, Region, Applications, Drivers, Trends & Forecast to 2018 to 2028 - 3rd...

What is Trending in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market? What are the Strategies to Boost Business in Near Years? -…

COVID-19 Updates We will be covering the overall impact of COVID -19 on the market value, market share & growth of the market and how the major players in the particular market are adapting these changes.

MarketResearchBazaar has added latest research report on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market, this report helps to analyze top manufacturers, regions, revenue, price, and also covers Industry sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

The global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market was valued at $XX million in 2019, and MAResearch analysts predict the global market size will reach $XX million by the end of 2026, growing at a CAGR of XX% between 2019 and 2026.

Download Premium Sample of the Report: http://marketresearchbazaar.com/requestSample/24200

In this report, the study analysis was given on a worldwide scale, for instance, present and traditional Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapiesgrowth analysis, competitive analysis, and also the growth prospects of the central regions. The report gives an exhaustive investigation of this market at country &, regional levels, and provides an analysis of the industry trends in each of the sub-segments, from sales, revenue and consumption. A quantitative and qualitative analysis of the main players in related regions is introduced, from the perspective of sales, revenue and price.

According to Research, the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market was valued at USD xxx million in 2019, and it is expected to reach a value of USD xxx million by 2026, at a CAGR of xx% over the forecast period 2021-2026. Correspondingly, the forecast analysis of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies industry comprises of Asia, North America, South America, Middle East and Africa, Europe, with the sales and revenue data in each of the sub-segments.

At the upcoming section, this report discusses industrial policy, economic environment, in addition to the fabrication processes and cost structures of the industry. And this report encompasses the fundamental dynamics of the market which include drivers, opportunities, and challenges faced by the industry. Additionally, this report showed a keen market study of the main consumers, raw material manufacturers and distributors, etc.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (M USD), market share and growth rate of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies in these regions, from 2014 to 2026 (forecast), covering

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

South America (Brazil, Argentina, Columbia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer, the top players including

Orange County Hair Restoration Center

Colorado Surgical Center&, Hair Institute

Evolution Hair Loss Institute

Hair Sciences Center of Colorado

Hair Transplant Institute of Miami

Anderson Center for Hair

Virginia Surgical Center

Savola Aesthetic Dermatology Center

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Platelet Rich Plasma Injections

Stem Cell Therapy

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies for each application, including

Dermatology Clinics

Hospitals

If you have any special requirements, please let us know and we will offer you the report as you want.

Enquiry Before Buying: http://marketresearchbazaar.com/enquiry/24200

Major Point of TOC:

Chapter One: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Overview

Chapter Two: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Player

Chapter Three: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Type

Chapter Four: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Application

Chapter Five: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Sales Channel

Chapter Six: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Region

Chapter Seven: Profile of Leading Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Players

Chapter Eight: Upstream and Downstream Analysis of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies

Chapter Nine: Development Trend of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies (2020-2029)

Chapter Ten: Appendix

Read Full Report: http://marketresearchbazaar.com/requestSample/24200

If you have any special requirements, please let us know and we will offer you the report as you want.

About (Market Research Bazaar):

Market Research Bazaar (MRB)- a part of VRRB Reports LLP is an overall Market Research and consulting organization. We give unparalleled nature of offering to our clients present all around the world crosswise over industry verticals. Market Research Bazaar has aptitude in giving profound jump showcase understanding alongside advertise knowledge to our clients spread across over different endeavours.

Media Contact:

UK: +442070973908

US: +13156360953

India: +919548234540

Email:[emailprotected]

Website:http://marketresearchbazaar.com/

Blog:http://marketresearchbazaar.com/blogs

Follows to Twitter : https://twitter.com/BazaarMrb

Follows to Linkdin : https://www.linkedin.com/company/market-research-bazaar-vrrb/

Excerpt from:

What is Trending in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market? What are the Strategies to Boost Business in Near Years? -...

In Remission for 10 Years: Long-term Data on CAR-T Therapy – Medscape

When a patient with cancer hears there isn't much left that doctors can do, it always stays fresh in the mind.

Doug Olson was first diagnosed with chronic lymphocytic leukemia (CLL) over 20 years ago, in 1996. For several years, his doctors used the watch-and-wait approach. But then his cancer progressed and needed treatment. By 2010, it had mutated so much that it no longer responded to standard therapy.

He was rapidly running out of options. Back then, the only treatment left was a bone marrow transplant. Without one, his doctors said, he would have 1 or 2 years left to live.

"I was really trying to avoid a bone marrow transplant. You're playing your last card if that doesn't work. It's a pretty rough procedure," Olson told Medscape Medical News.

Looking back, Olson counts himself as lucky for being in the right place, at the right time, with the right doctor. His oncologist was David Porter, MD, the principal investigator on a trial at the University of Pennsylvania that was investigating a brand new approach to treating cancer: chimeric antigen receptor (CAR) T-cell therapy.

CAR T-cell therapy uses a patient's own T cells engineered to express a receptor that targets proteins on cancer cells. CAR T cells are considered "living drugs" because they expand inside the body and stick around for years maybe for a lifetime to fight the cancer if it tries to come back.

"I was certainly intrigued by the approach. It had worked in mice, and it was the sort of thing that looked like it would work," Olson recalled.

Science is not a foreign language to Olson. He holds a PhD in medicinal chemistry, spent most of his career in the in vitro diagnostics industry, and currently acts as chief executive officer of Buhlmann Diagnostics Corp.

So he read the clinical protocol for the first in-human trial of CAR T cells and agreed to become patient number two.

Olson's T cells were harvested, engineered to attack the CD19 antigen found on malignant and normal B lymphocytes, and then were expanded into millions in the lab. After undergoing preconditioning with chemotherapy to minimize rejection and boost the CAR T cells' expansion inside the body, he received several infusions of the new therapy over the course of 3 days.

Nothing really happened for 2 weeks. Then he developed severe flu-like symptoms so bad that he was hospitalized.

Ironically, getting sick was a sign that the CAR T cells were working. Olson was experiencing one of the main short-term effects of CAR T-cell therapy: cytokine release syndrome. Symptoms include extremely high fevers and dangerous drops in blood pressure that can potentially cause end-organ damage.

In the early trials of these products, some patients experienced such a severe reaction that they needed intensive care, and some died. With increasing clinical experience, doctors have learned to control the reaction with the use of steroids and interleukein-6 inhibitors such as tocilizumab (Actemra).

Fortunately for Olson, the reaction passed, and he was eventually discharged.

Then the "aha moment" happened. Four weeks after receiving the CAR T cells, Olson found out that he was cancer free.

"It still gives me shivers," he said. "Dr Porter said, 'Your bone marrow's completely free. We just can't find a cancer cell anywhere.' "

The remission has lasted, and it is now 10 years later.

Long-term data have been accumulating for these novel therapies since Olson's treatment in 2010. This is particularly important for CAR T-cell therapy, because of its longevity. Because these are living cells and are expected to persist in the body for years, there is great interest in longer-term data, especially the risks for toxicity.

The FDA requires clinical follow-up for at least 15 years for patients treated with CAR T-cell therapy or any other genetically modified cells.

So far, most of the experience with CAR T cells comes from anti-CD19-directed therapy, which has shown "remarkable" remission rates in the 50% to 85% range, said Nirali Shah, MD, head of the hematologic malignancies section of the Pediatric Oncology Branch at the National Cancer Institute (NCI).

The most recent results presented at this year's annual meeting of the American Society of Clinical Oncology support earlier efficacy data, she noted. In the longest follow-up to date, researchers reported remissions lasting over 9 years in patients with relapsed/refractory B-cell lymphoma or CLL treated with Kite's axicaptagene cilleucel (Yescarta), one of two anti-CD19-directed CAR T-cell therapies approved by the FDA in 2017 (the other is Novartis' tisagenlecleucel [Kymriah]).

This study included 43 patients and showed an overall remission rate of 76%. Complete remission was achieved in 54% of patients, and 22% had partial remission.

The other focus is long-term safety. Although some of the long-term adverse effects are known and are manageable, others fall into the theoretical realm. In early May 2020, the NCI held a multidisciplinary virtual conference on CAR T-cell therapy "to encourage collaborative research about the subacute and potentially long-term toxicity profile of these treatments."

"We know just a little at this point about late- and long-term effects of CAR-T therapy, because we are relatively early in the era of CAR T cells," said Merav Bar, MD, from the Fred Hutchinson Cancer Research Center in Seattle, Washington.

What is known is that B-cell aplasia represents the most common long-term adverse effect of CAR T-cell therapy. B-cell aplasia results when anti-CD19 CAR-T therapy wipes out healthy B cells as well as the malignant ones responsible for leukemia/lymphoma.

As major players in the immune system, B cells are a key defense against viruses. So B-cell aplasia represents a very specific type of immunosuppression. It is generally less severe than immunosuppression that occurs after organ transplant, which hits the immune system pretty much across the board and carries a much higher risk for infection.

The main concern is what happens when someone with B-cell aplasia encounters a new pathogen, such as SARS-CoV-2.

After infection, B cells generate memory cells, which are not killed off by anti-CD19 therapy and that stick around for life. So a patient such as Olson would still make antibodies that fight infections they experienced before receiving CAR-T therapy, such as childhood chickenpox. But now they are unable to make new memory cells, so these patients receive monthly immunoglobulin infusions to protect against pathogens they have not previously encountered.

Olson takes this in stride and says he isn't overly worried about COVID-19. He follows the recommended precautions for a man his age. He wears a mask, washes his hands frequently, and tries to maintain social distancing. But he doesn't stay locked up in his New Hampshire home.

"I took the attitude when I was diagnosed with cancer that I'm going to live my life," he said. "Quality of life to me is more important than quantity."

Another problem is the possibility of neuropsychiatric toxicity. Past studies have reported a wide range of such toxicities associated with CAR T-cell therapy, including seizures and hallucinations. Most have occurred early in the course of treatment and appear to be short-lived and reversible. However, there remain questions about long-term neuropsychiatric problems.

In a long-term study of 40 patients with relapsed/refractory CLL, non-Hodgkin lymphoma, and ALL, nearly half of patients (47.5%, 19/40) self-reported at least one clinically meaningful negative neuropsychiatric outcome (anxiety, depression, or cognitive difficulty) 1 to 5 years after anti-CD19 CAR T-cell therapy. In addition, 37.5% (15/40) self-reported cognitive difficulties.

"Patients with more severe neurotoxicity showed a trend for more cognitive difficulties afterwards," said Bar, senior author of the study.

However, teasing out the role that CAR T-cell therapy plays in these problems poses a challenge. All of these patients had been heavily pretreated with previous cancer therapy, which has also been associated with neuropsychiatric problems.

"So far, we don't know what caused it," Bar said. "Nevertheless, people need to pay attention to neuropsychiatric symptoms in CAR T-cell therapy. It is important to continue to monitor these patients for these issues."

Another potential problem is graft-vs-host disease (GVHD). This is not uncommon after hematopoietic stem cell transplants. It develops when the donor T cells view antigens on healthy recipient cells as foreign and attack them.

For patients who are treated with CAR T cells, GVHD is mostly a concern among individuals who have previously had a transplant and who are already at increased risk for it.

In a study of late effects among 86 adults treated with anti-CD19 CAR T cells for relapsed/refractory non-Hodgkin lymphoma, Bar and colleagues found that GVHD occurred only among patients who had received a previous donor stem cell transplant. Of these, 20% (3/15) developed GVHD about 28 months after CAR-T therapy.

"The data for CAR T cells causing GVHD really hasn't shown that it's a huge problem, although we have seen it and are continuing to monitor for it," the NCI's Shah commented to Medscape Medical News.

A range of other long-term adverse effects have been reported with CAR-T therapy, including prolonged cytopenias (reduced mature blood cells), myelodysplasia (bone marrow failure), and second malignancies.

In the study with the longest follow-up to date, 16% (7/43) of patients developed second malignancies, which is comparable to data from Bar's study in Seattle (15%, 13/86). The researchers in this study consider this rate to be no higher than expected: these patients had already received extensive chemotherapy, which increases the risk for other cancers, they point out.

However, this brings up theoretical concerns about the long-term effects of gene modification. CAR T cells are engineered using retroviruses (mainly lentiviruses), which randomly insert the CAR genes into the host genome. Doing so may cause mutations that could promote cancer. These lentiviruses also carry the theoretical risk of becoming capable of viral replication once inside the body.

To address these concerns, viruses used to engineer CAR T cells go through comprehensive safety testing. After therapy, patients are checked every few months during the first year and annually after that.

So far, there have been no reports of cancers associated with CAR T-cell therapy.

"Any type of cancer is a very theoretical risk," Bar told Medscape Medical News. "Most likely the malignancies in our study were related to prior treatment that the patients received. None of them had any evidence of replication-competent lentivirus, or any other evidence that the malignancies were related to the CAR T cells."

Another theoretical concern is the possibility of new-onset autoimmune disease, although, once again, no cases have been reported so far.

"We think of it as a theoretic possibility. Whenever you jack up the immune system, autoimmune disease is a potential risk," said Carl June, MD, director of the Center for Cellular Immunotherapies at the University of Pennsylvania.

June was the coprincipal investigator of the trial in which Olson participated. He is also the inventor on patents for CAR T cells licensed by the University of Pennsylvania to Novartis and Tmunity and is a scientific founder with equity in Tmunity.

Still, autoimmunity could occur, and scientists are looking out for it.

"We are continuing to be vigilant in our monitoring for autoimmune disease," Shah added. "We've been doing CAR T-cell therapy since 2012, and I think we have yet to see true autoimmunity beyond GVHD."

In the 10 years since Olson received CAR T-cell therapy, an entire industry has sprung up. Over 100 companies worldwide are now developing CAR T-cell therapies targeting various antigens. These therapies are directed at about 60 different tumor types, including solid tumors. Nearly 200 clinical trials are underway, though most are still in early stages: as of September 2019, only 5% had reached phase 3.

Clinical data show promising results for CAR T-cell therapy directed against CD22 (overexpressed on ALL cells), and BCMA (found on almost all multiple myeloma cells). Yet questions remain as to whether CAR T cells will be as effective if they target antigens other than CD19 or cells other than B lymphocytes. One of the biggest research questions is whether they will be effective against solid tumors.

One research avenue being watched with great interest is the development of universal CAR T cells. So far, such products are at very early stages of development (phase 1 trials), but they are attractive because of the potential advantages they offer over bespoke CAR T cells. Automating the process holds the promise of immediate availability, standardizing production, expanding access, and lowering costs. And because the T cells for this universal product come from healthy donors, they may function better than T cells that have been battered and bruised by past cancer treatments, or even the cancer itself.

However, precisely because they are developed from healthy donor T cells, universal CAR T cells may pose increased risk for GVHD. Scientists are trying to get around this problem by engineering universal CAR T cells that lack the T-cell receptor involved in GVHD.

There are also other concerns. Nature has a penchant for mutation. Engineering CAR T cells without T-cell receptors means the body may no longer detect or reject a universal CAR T cell if it goes rogue. Also, gene insertion in universal CAR-T therapy is targeted rather than random (as in bespoke CAR T cells), which could create off-target effects. Both issues create a theoretical risk of such products inducing an untreatable CAR T-cell therapyassociated cancer.

"The theoretic risk with universal cells is that their safety profile may not be as good for long term," June commented.

From that first trial in which June and Porter used CAR T cells, two of three patients they treated are still alive 10 years later.

Olson is one of these two, and he still undergoes monitoring every 3 months to check for relapse. So far, none of his tests have shown signs of his cancer returning.

After going into remission, Doug spent the next 6 to 9 months regaining his health and strength.

"I figured if I had this amazing treatment that saved my life, I had an obligation to stay alive," he said. "I'd better not die of something like a heart attack!"

He took up long distance running and has completed six half marathons. He became involved in the Leukemia and Lymphoma Society, participating in fund-raising and helping newly diagnosed patients. Over the years, he has also given talks for researchers, people with cancer, and healthcare providers.

Doug is now 73. Today, he marvels at how rapidly the CAR-T field has progressed.

"Twenty years ago, if you had cancer, your prospects weren't nearly as good as these days. In 2010, people still didn't believe in CAR T-cell therapy," he said. "My goal always in telling my story is a message of hope."

For more from Medscape Oncology, join us on Twitter and Facebook.

The rest is here:

In Remission for 10 Years: Long-term Data on CAR-T Therapy - Medscape

COVID-19 Fibroblast Based Cell Therapy Candidate Shown to Reduce Lung Scarring in Aggressive Animal Model – Tyler Morning Telegraph

HOUSTON, July 21, 2020 /PRNewswire/ --FibroGenesis announced today new data supporting use of its PneumoBlast product in the battle against COVID-19.Using the widely accepted bleomycin model of lung scarring (fibrosis), Company scientists have demonstrated the administration and use of PneumoBlast induced a 51% reduction of lung fibrosis,which was statistically significant (p < .005). Importantly, when PneumoBlast was compared head to head with bone marrow derived mesenchymal stem cells (BMSCs) for COVID-19, PneumoBlast was 221% more effective. In producing the potent anti-inflammatory protein interleukin 1 receptor antagonist, which is believed to be the mechanism of scar tissue prevention by BMSC therapies currently in development, PneumoBlast was 192% more effective than BMSCs which was again, statistically significant(p < .005).

During an interview with Healthline.com, Dr. Lori Shah, transplant pulmonologist at New York-Presbyterian/Columbia University Irving Medical Center, stated "Holes in the lungs likely refers to an entity that has been dubbed 'post-COVID fibrosis,' otherwise known as post-ARDS [acute respiratory distress syndrome] fibrosis, which is irreversible and can result in severe functional limitations from patients, such as cough, shortness of breath, and need for oxygen." It has been reported that pulmonary fibrosis due to COVID-19 is occurring in increasing numbers of patients in their 20s and 30s.

"COVID-19 represents a new clinical entity which not only causes death through lung inflammation, but in some patients causes permanent lung injury through stimulation of scarring," said Tom Ichim, Ph.D., Chief Scientific Officer of FibroGenesis. "The prospects that our cell therapy approach not only possesses therapeutic effects on animal models of the acute stage of COVID-19, but also benefits the long-term pathology, has our research team extremely excited."

"As the scientific and medical community is discovering more about the biological and medical consequences of the COVID-19 infection, FibroGenesis is eager to contribute to the therapeutic cure options currently being created to fight this global war against an invisible enemy," commented Pete O'Heeron, President/CEO of FibroGenesis. "While we are excited about potential vaccines in the pipeline, the fact remains that there are 3.8 million confirmed cases of COVID-19 in the U.S. and we do not know what the long-term outcomes for these patients will be. To our knowledge, we are the only cell therapy company which is creating a therapy to resolve the initial pathology of infection and also proactively tackling its long-term consequences."

About FibroGenesis

Based in Houston, Texas, FibroGenesis, is a regenerative medicine company developing an innovative solution for chronic disease treatment using human dermal fibroblasts. Currently, FibroGenesis holds 235+ U.S. and international issued patents/patents pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure, Colitis and Heart Failure. Funded entirely by angel investors, FibroGenesis represents the next generation of medical advancement in cell therapy.

Visit http://www.Fibro-Genesis.com.

Go here to see the original:

COVID-19 Fibroblast Based Cell Therapy Candidate Shown to Reduce Lung Scarring in Aggressive Animal Model - Tyler Morning Telegraph

Global Stem Cell Therapy Market 2020 Industry (Covid-19 Impact) Size, Share, Trend and Forecast 2025: Anterogen Co. Ltd., MEDIPOST Co. Ltd., Osiris…

Stem Cell Therapy Market analysis is provided for the international markets including development trends, competitive landscape analysis, geography, end-users, applications, market share, COVID-19 analysis, and forecast 2020-2025. The predictions estimated in the market report have been resulted in using proven research techniques, methodologies, and assumptions. This Stem Cell Therapy market report states the market overview, historical data along with size, growth, share, demand, and revenue of the global industry.

Global Stem Cell Therapy Market study with 100+ market data Tables, Pie Chat, Graphs & Figures is now released by Adroit Market Research. The report presents a complete assessment of the Market covering future trends, current growth factors, attentive opinions, facts and industry-validated market data forecast until 2025.

Get sample copy of Stem Cell Therapy Market [emailprotected] https://www.adroitmarketresearch.com/contacts/request-sample/691

The research report on Stem Cell Therapy Market provides a comprehensive analysis of the market status and development trend, including types, applications, growth, opportunities, rising technology, competitive landscape and product offerings of key players. Stem Cell Therapy Market report covers the present and past market scenarios, market development patterns, and is likely to proceed with a continuing development over the forecast period. Stem Cell Therapy Market report provides in-depth statistics and analysis available on the market status of the Stem Cell Therapy key players and is a valuable method of obtaining guidance and direction for companies and business enterprise insider considering the Stem Cell Therapy market. It contains the analysis of drivers, challenges, and restraints impacting the industry.

Top Leading Key Players are:Anterogen Co., Ltd. (South Korea), MEDIPOST Co., Ltd. (South Korea), Osiris Therapeutics, Inc. (U.S.) and Pharmicell Co., Ltd.

Read complete report with TOC at: https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market

The segmentation chapter allows readers to understand aspects of the Global Stem Cell Therapy Market such as types, available technologies, and applications. These chapters are written in a way that describes years of development and the process that will take place in the next few years. The research report also provides insightful information on new trends that are likely to define the progress of these segments over the next few years.

Global Stem Cell Therapy market is segmented based by type, application and region.

Based on Type, the market has been segmented into:Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Based on Application, the market has been segmented into:Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

Regional and Country- level Analysis Stem Cell Therapy market of different geographical areas are studied deeply and an economical scenario has been offered to support new entrants, leading market players, and investors to regulate emerging economies. The top producers and consumers focus on production, product capacity, value, consumption, growth opportunity, and market share in these key regions, covering

Stem Cell Therapy Market Segment by Regions, regional analysis covers North America Europe Asia-Pacific South America Middle East and Africa

Stakeholders Benefit:1. Analysis of emerging trends, and key market dynamics.2. Comprehensive analysis of products and segmentation.3. Competitive analysis and key strategies followed by the key players in the market.4. PEST and Poster analysis, and many more.5. COVID-19 Impact detailed analysis.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691

About Us:Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us:Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read more here:

Global Stem Cell Therapy Market 2020 Industry (Covid-19 Impact) Size, Share, Trend and Forecast 2025: Anterogen Co. Ltd., MEDIPOST Co. Ltd., Osiris...

Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2027 : Which technology is expected to trend higher? – 3rd Watch News

Autologous stem-cell transplantation is the autologous transplantation of stem cells. User preserves his own cells which can be used later. This is considered to be one of the effective and safer way to treat the diseases such as cancer. It is safer technology when compared with allogeneic and xeno transplants. IT reduces the risk of disease transmission, bio-incompatibility, and immunological reactions.

Download a Sample Report Explore further @https://www.theinsightpartners.com/sample/TIPRE00006725

The Autologous Stem Cell and Non-Stem Cell Based Therapies market is anticipated to grow in the forecast period owing to driving factors such as rising prevalence of cancer and diabetes, growing geriatric population, favorable reimbursement scenarios across several countries.

Top Dominating Key Players:

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies market is segmented on the basis of application and end user. Based on application the market is segmented into Neurodegenerative, Cardiovascular, Cancer & Autoimmune, Skin and Infectious Diseases. Based on end user, the market is segmented into hospital and research institute.

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Autologous Stem Cell and Non-Stem Cell Based Therapies market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Autologous Stem Cell and Non-Stem Cell Based Therapies market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Autologous Stem Cell and Non-Stem Cell Based Therapies market in these regions.

Request for Buy Report @https://www.theinsightpartners.com/buy/TIPRE00006725

Reasons to Buy the Report:

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

The Insight partners,

Phone: +1-646-491-9876Email:[emailprotected]

See more here:

Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2027 : Which technology is expected to trend higher? - 3rd Watch News

Growing Infrastructure Development Projects in Asia-Pacific to Fuel Growth of the Animal Stem Cell Therapy Market 2017 2025 – Bulletin Line

According to the latest report published by PMR, the Animal Stem Cell Therapy market is anticipated to grow at a steady pace over the forecast period (2019-2029). The report sheds light on the various trends and restraining factors that are expected to shape the growth of the Animal Stem Cell Therapy in the upcoming years. The report ponders over the various parameters that are expected to impact revenue generation, sales, and demand for the Animal Stem Cell Therapy in the various regional markets.

According to the study, the Animal Stem Cell Therapy market is likely to attain a market value of ~US$ XX by 2019 and grow at a CAGR of ~XX% during the assessment period. The market study introspects the competition landscape of the Animal Stem Cell Therapy market and highlights the key developments and technological innovations witnessed in the current Animal Stem Cell Therapy market landscape.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/14941

Key findings of the Animal Stem Cell Therapy market report:

Animal Stem Cell Therapy Market Segmentation

The report dissects the Animal Stem Cell Therapy market into different segments to provide a fair understanding of the different aspects of the Animal Stem Cell Therapy market.

The regional analysis of the Animal Stem Cell Therapy market sheds light on the growth prospects of the Animal Stem Cell Therapy market in different regions. The current market trends, the impact of regulatory policies, market share, size, and value of each regional market are presented in the report supported by easy-to-understand graphs and tables.

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/14941

Key Questions Related to the Animal Stem Cell Therapy Market Addressed in the Report

Why Choose PMR?

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/14941

More here:

Growing Infrastructure Development Projects in Asia-Pacific to Fuel Growth of the Animal Stem Cell Therapy Market 2017 2025 - Bulletin Line

Restorative therapies for erectile dysfunction: Where are we at in 2020? – Urology Times

Restorative therapies are an exciting area of potential treatments for patients with erectile dysfunction (ED); however, there is a paucity of clinical data regarding their efficacy and safety, according to Trinity Bivalacqua, MD, PhD.1

The goal of restorative therapies in ED is to reestablish whole-organ function and reverse penile dysfunction using regenerative medicine technology, Bivalacqua explained in a presentation during the 2020 AUA Virtual Experience. The restorative therapies for ED include platelet rich plasma (PRP), stromal vascular fraction (SVF), amniotic fluid (AF), and stem cells (mesenchymal cells, adipose derived stem cells, amniotic stem cells, and cord blood stem cells).

Restorative therapies are particularly relevant for patients who have had radical prostatectomies and have post-prostectomy ED, as well as for patients with severe ED as it relates to peripheral vascular disease and diabetes, said Bivalacqua, director of Urologic Oncology at Johns Hopkins Univsersity.

Although the potential of restorative therapy to treat ED itself, and not just its symptoms, has created a lot of buzz in the urology community, Bivalacqua said the lack of data in the literature backing the efficacy and safety of the technology means it should currently be reserved for clinical trials. Accordingly, this is the current position of the Sexual Medicine Society of North America (SMSNA), which sponsored Bivalacquas discussion:

Given the lack of regulatory agency approval for any restorative (regenerative) therapies for the treatment of ED and until such time as approval is granted, SMSNA believes that the use of shock waves or stem cells or platelet rich plasma is experimental and should be conducted under research protocols (clinical trials) in compliance with Institutional Review Board approval.

In his discussion during the AUA online platform, Bivalacqua discussed the limited available evidence in the literature for each ED-focused restorative therapy and the next steps for this technology.

PRP is the most common restorative therapy used for ED. This treatment can be applied through intracavernous injection. Although he did not make a recommendation for its use outside of clinical trials, Bivalacqua said PRP Falls under the HCT/P 361 exemption proposed by the FDA. This means in clinical practice you can usePRPwithout gaining FDA approval. As long as the tissue/biospecimen is not manipulated once its removed from the patient, it is then exempt from FDA approval and clinical trials.

With PRP, a clinician can use a normal centrifuge to isolate the PRP, which can then be injected. It does not have a specific CPT billing code, but can be categorized under a nonspecific code for blood transfusion and reinfection. For the most part, it is not covered by insurance or Medicare, with the post common payment form being cash, said Bivalacqua. Regarding clinical evidence, there have been no randomized clinical trials of PRP.

Bivalacqua said there is 1 peer-reviewed trial2 of PRP in the literature, but it only had safety results. The study assessed PRP in 17 patients with various urological diseases, including 4 patients with ED. The results showed that PRP injections were safe overall, with some mild bruising, but no serious adverse events.

Autologous SVF involves the removal of adipose tissues, often through liposuction. The removed tissues are then separated into individual components, with the key components, such as adipose-derived stemcells(ADSCs)and endothelial precursorcells(EPCs), being reinjected into the patient. ADSCs and EPCs release beneficial cytokines and growth hormones, which promote tissue survival, angiogenesis, and further stem cell recruitment, said Bivalacqua.

Since SVF involves the patient specimens being manipulated, unlike with PRP, this procedure does not fall under the FDA HCT/P 361 exemption and no SVF devices are currently FDA approved. There is also no clinical trial data in the literature supporting the efficacy of SVF.

Some trials have been published showing promise for low-intensity shockwave therapy as a treatment for patients with ED. One study3 looked at the long-term efficacy of low-intensity shockwave therapy using an electrohydraulic device in 156 patients who initially had a successful outcome according to the minimal clinically important difference on the International Index of Erectile Function-Erectile Function (IIEF-EF). Patients were assessed per the IIEF-EF at 6, 12, 18, and 24 months.

Although the treatment was successful in 63.5% (n = 99) of patients at 1 month after treatment, efficacy gradually decreased over time. Among the 99 patients who initially responded, only 53 (53.5%) were still experiencing a beneficial treatment effect at 2 years follow-up.

They found that there was very little durability of the shock-wave therapy in patients with severe ED. Whatever effect was seen was then mitigated at 24 months, said Bivalacqua. Those patients with non-severe EDthose who would typically respond to PDE-5 inhibitorshad a more efficacious response.

Another study4 of low-intensity shockwave therapy used an electromagnetic device to treat patients with ED. There were 87 evaluable patients who were randomized to receive 1 of 2 shockwave regimens: Group A (n= 45) received 3600 shocks (720/day) over 5 days and Group B (n = 42) received 3600 shocks over 2 weeks (600 over 3 days each week). The was a statistically significant improvement in IIEF-EF score for both groups, with a mean increase of 2.7 in both group A and group B (P <.05). There was also a statistically significant improvement in Erectile Hardness Scale score in both arms at 0.6 points in group A and 0.5 points in group B.

Although the improvements were statistically significant, the benefits were minor, leaving Bivalacqua to ask, The question is, Is this clinically significant? My perspective on this is that this did not include a sham group and the improvement was in patients who were typically PDE-5inhibitorresponders. But I do think we have to acknowledge that using the electromagnetic probe, which causes a lower peak energy, may be safer for patients.

While it is an exciting field, Bivalacqua noted that there is an ugly side to restorative therapies for ED

The global use of PRP, especially in North America, is very high, despite the lack of any clinical evidence that it is effective or safe, said Bivalacqua, adding, Some practitioners are cashing in on the hype of shockwave therapy even though the treatments are not FDA approved.

To combat these issues, Bivalacqua said several questions need to be answered in the literature. The next steps with restorative therapies are determining optimal dosing regimens; assessing the total power and number of shocks with shockwave devices; determining the optimal device choiceelectromagnetic versus electrohydraulic; and evaluating the duration of studies and role of maintenance therapy. But more importantly, we need to have a sham in randomized controlled trials.

Bivalacqua also provided several suggestions on how the efficacy of the available restorative therapies could be improved.

The future is combination therapy, where we include low-intensity shockwave therapy with the injection of either SVF or stem cells. And we have to include a maintenance phase. Other protein- and gene-based therapies, such as SDF-1, which hone stem cells, are obviously an important next step. And neurotrophic factors placed at the time of radical prostatectomy are the only way that we are going to be able to regenerate nerves post prostatectomy.

References

1. Bivalacqua T. State-of-the-Art Lecture: Update on Clinical Trials on Restorative Therapies for Erectile Dysfunction. Presented during 2020 AUA Virtual Experience. June 27-28, 2020.

2. Matz EL, Pearlman AM, Terlecki RP, et al. Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions. Investig Clin Urol. 2018;59(1):61-65. doi: 10.4111/icu.2018.59.1.61

3. Kitrey ND, Vardi Y, Appel B, et al. Low intensity shock wave treatment for erectile dysfunction-how long does the effect last? J Urol 2018;200(1):167-170.doi: 10.1016/j.juro.2018.02.070

4. Patel P, Katz J, Lokeshwar SD, et al. Phase II randomized, clinical trial evaluating 2 schedules of low-intensity shockwave therapy for the treatment of erectile dysfunction. Sex Med. 2020 Jun; 8(2): 214222. doi: 10.1016/j.esxm.2020.01.010

View post:

Restorative therapies for erectile dysfunction: Where are we at in 2020? - Urology Times

New Trend: Animal Stem Cell Therapy Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 | Medivet Biologics LLC, VETSTEM…

LOS ANGELES, United States: The research report published by QYResearch gives the potential headway openings that prevails in the global market. Market study of the global Animal Stem Cell Therapy market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Animal Stem Cell Therapy industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Animal Stem Cell Therapy production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

Key companies operating in the global Animal Stem Cell Therapy market include _ Medivet Biologics LLC, VETSTEM BIOPHARMA, J-ARM, U.S. Stem Cell, Inc, VetCell Therapeutics, Celavet Inc., Magellan Stem Cells, Kintaro Cells Power, Animal Stem Care, Animal Cell Therapies, Cell Therapy Sciences, Animacel

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1427718/global-animal-stem-cell-therapy-market

Segmental Analysis

The report has classified the global Animal Stem Cell Therapy industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Animal Stem Cell Therapy manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Animal Stem Cell Therapy industry.

Global Animal Stem Cell Therapy Market Segment By Type:

, Dogs, Horses, Others

Global Animal Stem Cell Therapy Market Segment By Application:

, Veterinary Hospitals, Research Organizations Key Players: The Key manufacturers that are operating in the

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Animal Stem Cell Therapy industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Animal Stem Cell Therapy market include _ Medivet Biologics LLC, VETSTEM BIOPHARMA, J-ARM, U.S. Stem Cell, Inc, VetCell Therapeutics, Celavet Inc., Magellan Stem Cells, Kintaro Cells Power, Animal Stem Care, Animal Cell Therapies, Cell Therapy Sciences, Animacel

Key questions answered in the report:

Enquire Customization in The Report: https://www.qyresearch.com/customize-request/form/1427718/global-animal-stem-cell-therapy-market

TOC

Table of Contents 1 Animal Stem Cell Therapy Market Overview1.1 Product Overview and Scope of Animal Stem Cell Therapy1.2 Animal Stem Cell Therapy Segment by Type1.2.1 Global Animal Stem Cell Therapy Sales Growth Rate Comparison by Type (2021-2026)1.2.2 Dogs1.2.3 Horses1.2.4 Others1.3 Animal Stem Cell Therapy Segment by Application1.3.1 Animal Stem Cell Therapy Sales Comparison by Application: 2020 VS 20261.3.2 Veterinary Hospitals1.3.3 Research Organizations1.4 Global Animal Stem Cell Therapy Market Size Estimates and Forecasts1.4.1 Global Animal Stem Cell Therapy Revenue 2015-20261.4.2 Global Animal Stem Cell Therapy Sales 2015-20261.4.3 Animal Stem Cell Therapy Market Size by Region: 2020 Versus 2026 2 Global Animal Stem Cell Therapy Market Competition by Manufacturers2.1 Global Animal Stem Cell Therapy Sales Market Share by Manufacturers (2015-2020)2.2 Global Animal Stem Cell Therapy Revenue Share by Manufacturers (2015-2020)2.3 Global Animal Stem Cell Therapy Average Price by Manufacturers (2015-2020)2.4 Manufacturers Animal Stem Cell Therapy Manufacturing Sites, Area Served, Product Type2.5 Animal Stem Cell Therapy Market Competitive Situation and Trends2.5.1 Animal Stem Cell Therapy Market Concentration Rate2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)2.6 Manufacturers Mergers & Acquisitions, Expansion Plans2.7 Primary Interviews with Key Animal Stem Cell Therapy Players (Opinion Leaders) 3 Animal Stem Cell Therapy Retrospective Market Scenario by Region3.1 Global Animal Stem Cell Therapy Retrospective Market Scenario in Sales by Region: 2015-20203.2 Global Animal Stem Cell Therapy Retrospective Market Scenario in Revenue by Region: 2015-20203.3 North America Animal Stem Cell Therapy Market Facts & Figures by Country3.3.1 North America Animal Stem Cell Therapy Sales by Country3.3.2 North America Animal Stem Cell Therapy Sales by Country3.3.3 U.S.3.3.4 Canada3.4 Europe Animal Stem Cell Therapy Market Facts & Figures by Country3.4.1 Europe Animal Stem Cell Therapy Sales by Country3.4.2 Europe Animal Stem Cell Therapy Sales by Country3.4.3 Germany3.4.4 France3.4.5 U.K.3.4.6 Italy3.4.7 Russia3.5 Asia Pacific Animal Stem Cell Therapy Market Facts & Figures by Region3.5.1 Asia Pacific Animal Stem Cell Therapy Sales by Region3.5.2 Asia Pacific Animal Stem Cell Therapy Sales by Region3.5.3 China3.5.4 Japan3.5.5 South Korea3.5.6 India3.5.7 Australia3.5.8 Taiwan3.5.9 Indonesia3.5.10 Thailand3.5.11 Malaysia3.5.12 Philippines3.5.13 Vietnam3.6 Latin America Animal Stem Cell Therapy Market Facts & Figures by Country3.6.1 Latin America Animal Stem Cell Therapy Sales by Country3.6.2 Latin America Animal Stem Cell Therapy Sales by Country3.6.3 Mexico3.6.3 Brazil3.6.3 Argentina3.7 Middle East and Africa Animal Stem Cell Therapy Market Facts & Figures by Country3.7.1 Middle East and Africa Animal Stem Cell Therapy Sales by Country3.7.2 Middle East and Africa Animal Stem Cell Therapy Sales by Country3.7.3 Turkey3.7.4 Saudi Arabia3.7.5 U.A.E 4 Global Animal Stem Cell Therapy Historic Market Analysis by Type4.1 Global Animal Stem Cell Therapy Sales Market Share by Type (2015-2020)4.2 Global Animal Stem Cell Therapy Revenue Market Share by Type (2015-2020)4.3 Global Animal Stem Cell Therapy Price Market Share by Type (2015-2020)4.4 Global Animal Stem Cell Therapy Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global Animal Stem Cell Therapy Historic Market Analysis by Application5.1 Global Animal Stem Cell Therapy Sales Market Share by Application (2015-2020)5.2 Global Animal Stem Cell Therapy Revenue Market Share by Application (2015-2020)5.3 Global Animal Stem Cell Therapy Price by Application (2015-2020) 6 Company Profiles and Key Figures in Animal Stem Cell Therapy Business6.1 Medivet Biologics LLC6.1.1 Corporation Information6.1.2 Medivet Biologics LLC Description, Business Overview and Total Revenue6.1.3 Medivet Biologics LLC Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.1.4 Medivet Biologics LLC Products Offered6.1.5 Medivet Biologics LLC Recent Development6.2 VETSTEM BIOPHARMA6.2.1 VETSTEM BIOPHARMA Animal Stem Cell Therapy Production Sites and Area Served6.2.2 VETSTEM BIOPHARMA Description, Business Overview and Total Revenue6.2.3 VETSTEM BIOPHARMA Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.2.4 VETSTEM BIOPHARMA Products Offered6.2.5 VETSTEM BIOPHARMA Recent Development6.3 J-ARM6.3.1 J-ARM Animal Stem Cell Therapy Production Sites and Area Served6.3.2 J-ARM Description, Business Overview and Total Revenue6.3.3 J-ARM Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.3.4 J-ARM Products Offered6.3.5 J-ARM Recent Development6.4 U.S. Stem Cell, Inc6.4.1 U.S. Stem Cell, Inc Animal Stem Cell Therapy Production Sites and Area Served6.4.2 U.S. Stem Cell, Inc Description, Business Overview and Total Revenue6.4.3 U.S. Stem Cell, Inc Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.4.4 U.S. Stem Cell, Inc Products Offered6.4.5 U.S. Stem Cell, Inc Recent Development6.5 VetCell Therapeutics6.5.1 VetCell Therapeutics Animal Stem Cell Therapy Production Sites and Area Served6.5.2 VetCell Therapeutics Description, Business Overview and Total Revenue6.5.3 VetCell Therapeutics Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.5.4 VetCell Therapeutics Products Offered6.5.5 VetCell Therapeutics Recent Development6.6 Celavet Inc.6.6.1 Celavet Inc. Animal Stem Cell Therapy Production Sites and Area Served6.6.2 Celavet Inc. Description, Business Overview and Total Revenue6.6.3 Celavet Inc. Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.6.4 Celavet Inc. Products Offered6.6.5 Celavet Inc. Recent Development6.7 Magellan Stem Cells6.6.1 Magellan Stem Cells Animal Stem Cell Therapy Production Sites and Area Served6.6.2 Magellan Stem Cells Description, Business Overview and Total Revenue6.6.3 Magellan Stem Cells Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.4.4 Magellan Stem Cells Products Offered6.7.5 Magellan Stem Cells Recent Development6.8 Kintaro Cells Power6.8.1 Kintaro Cells Power Animal Stem Cell Therapy Production Sites and Area Served6.8.2 Kintaro Cells Power Description, Business Overview and Total Revenue6.8.3 Kintaro Cells Power Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.8.4 Kintaro Cells Power Products Offered6.8.5 Kintaro Cells Power Recent Development6.9 Animal Stem Care6.9.1 Animal Stem Care Animal Stem Cell Therapy Production Sites and Area Served6.9.2 Animal Stem Care Description, Business Overview and Total Revenue6.9.3 Animal Stem Care Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.9.4 Animal Stem Care Products Offered6.9.5 Animal Stem Care Recent Development6.10 Animal Cell Therapies6.10.1 Animal Cell Therapies Animal Stem Cell Therapy Production Sites and Area Served6.10.2 Animal Cell Therapies Description, Business Overview and Total Revenue6.10.3 Animal Cell Therapies Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.10.4 Animal Cell Therapies Products Offered6.10.5 Animal Cell Therapies Recent Development6.11 Cell Therapy Sciences6.11.1 Cell Therapy Sciences Animal Stem Cell Therapy Production Sites and Area Served6.11.2 Cell Therapy Sciences Animal Stem Cell Therapy Description, Business Overview and Total Revenue6.11.3 Cell Therapy Sciences Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.11.4 Cell Therapy Sciences Products Offered6.11.5 Cell Therapy Sciences Recent Development6.12 Animacel6.12.1 Animacel Animal Stem Cell Therapy Production Sites and Area Served6.12.2 Animacel Animal Stem Cell Therapy Description, Business Overview and Total Revenue6.12.3 Animacel Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.12.4 Animacel Products Offered6.12.5 Animacel Recent Development 7 Animal Stem Cell Therapy Manufacturing Cost Analysis7.1 Animal Stem Cell Therapy Key Raw Materials Analysis7.1.1 Key Raw Materials7.1.2 Key Raw Materials Price Trend7.1.3 Key Suppliers of Raw Materials7.2 Proportion of Manufacturing Cost Structure7.3 Manufacturing Process Analysis of Animal Stem Cell Therapy7.4 Animal Stem Cell Therapy Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers8.1 Marketing Channel8.2 Animal Stem Cell Therapy Distributors List8.3 Animal Stem Cell Therapy Customers 9 Market Dynamics 9.1 Market Trends 9.2 Opportunities and Drivers 9.3 Challenges 9.4 Porters Five Forces Analysis 10 Global Market Forecast10.1 Global Animal Stem Cell Therapy Market Estimates and Projections by Type10.1.1 Global Forecasted Sales of Animal Stem Cell Therapy by Type (2021-2026)10.1.2 Global Forecasted Revenue of Animal Stem Cell Therapy by Type (2021-2026)10.2 Animal Stem Cell Therapy Market Estimates and Projections by Application10.2.1 Global Forecasted Sales of Animal Stem Cell Therapy by Application (2021-2026)10.2.2 Global Forecasted Revenue of Animal Stem Cell Therapy by Application (2021-2026)10.3 Animal Stem Cell Therapy Market Estimates and Projections by Region10.3.1 Global Forecasted Sales of Animal Stem Cell Therapy by Region (2021-2026)10.3.2 Global Forecasted Revenue of Animal Stem Cell Therapy by Region (2021-2026)10.4 North America Animal Stem Cell Therapy Estimates and Projections (2021-2026)10.5 Europe Animal Stem Cell Therapy Estimates and Projections (2021-2026)10.6 Asia Pacific Animal Stem Cell Therapy Estimates and Projections (2021-2026)10.7 Latin America Animal Stem Cell Therapy Estimates and Projections (2021-2026)10.8 Middle East and Africa Animal Stem Cell Therapy Estimates and Projections (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See the article here:

New Trend: Animal Stem Cell Therapy Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 | Medivet Biologics LLC, VETSTEM...

International Society for Stem Cell Application ISSCA to Launch Postgraduate Studies Program in Stem Cell Therapies and Regenerative Medicine in…

The international Society for Stem Cell Application ISSCA and Medicel Chile have announced plans to launch a post graduate studies program in stem cell therapies and regenerative medicine in 2020.

The program will include Seven days of intensive, interactive training coursework with classroom instruction and laboratory practice through didactic lectures, hands-on practical experience in laboratory protocols and relevant lessons in regulatory practices. Medicels Chief Scientific Officer and Other leading Scientists will teach the coursework and perform laboratory instruction, accompanied by a series of guest lecturers from the Global Stem Cells Group faculty of scientists.

Attendees will receive hands-on training in techniques for a variety of laboratory processes, and gain insight into the inner workings of a cGMP laboratory and registered tissue bank. Regenerative medicine experts with more 15 years of experience in the field will train attendees and provide the necessary tools to implement regulatory and clinical guidelines in a cGMP laboratory setting

The graduate course will be scheduled 3 times during 2020 starting February 23rd

Our end goal in Launching this Fellowship program is to help physicians that are looking for really advanced and formal training in Cellular Therapies and Regenerative Medicine We want to provide them the necessary skills and in depth specialization that is lacking in our smaller point of care programs , noted Benito Novas ISSCA Public Relations Director

To learn more about the February 2020 certification event in Santiago, or any of the other upcoming certification courses around the world, visit the ISSCA website. http://www.issca.us

About the International Society for Stem Cells Applications (ISSCA)

The International Society for Stem Cells Applications (ISSCA) is a multidisciplinarycommunity of scientists and physicians, all of whom aspire to treat diseases and lessenhuman suffering through advances in science, technology, and the practice of regenerativemedicine. Incorporated and Trademarked in the United States of America as a non-profit entity, ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine.Their code of ethics emphasizes principles of morals and ethical conducts.

ISSCAs vision is to take a leadership position in promoting excellence and settingstandards in the regenerative medicine fields of publication, research, education, training,and certification. ISSCA serves its members through advancements made to the specialtyof regenerative medicine. They aim to encourage more physicians to practice regenerativemedicine and make it available to benefit patients both nationally and globally.

For more information, please visit the ISSCAs website or send an email toinfo@stemcellsgroup.com

About Medicel Chile

Medicel Chile is one of the premiere regenerative medicine treatment centers in the country of Chile, conveniently located in Santiago de Chile, one of the largest metropolitan areas in Latin America. Medicel carries with it a reputation as one of the most scientifically advanced and professional regenerative medicine Laboratories in Chile, and this is in no small part due to its highly-qualified team of scientists and medical professionals and advisers, who research tirelessly to head new breakthroughs in the fields of cellular therapy and cryopreservation, which is the freezing of a stem cell sample to ensure its longevity and freshness, should the patient receiving the service ever wish to use their frozen cells for some future malady.

About International Society for Stem Cells Applications

The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine. Their code of ethics emphasizes principles of morals and ethical conducts.

At ISSCA, their vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerativemedicine and make it available to benefit patients both nationally and globally.

For more information, please visit https://www.issca.us/ or send an email to info@stemcellsgroup.com

Excerpt from:

International Society for Stem Cell Application ISSCA to Launch Postgraduate Studies Program in Stem Cell Therapies and Regenerative Medicine in...

Tag: Stem Cell Therapy Growth – Cole of Duty

"Global Stem Cell Therapy Market Assessment Report: Present & Forecast Evaluation"is a comprehensive blend of qualitative and quantitative analysis in terms of Stem Cell Therapy market size, demand, revenue, gross margin, value, and volume. The whole research study is segmented based on regions, product type, application, and top companies operating in Stem Cell Therapy Market. The report begins with the introduction on Stem Cell Therapy Industry, drivers, restraints, trends, PEST analysis, PORTERs Five Forces analysis. The macro-economic factors, Stem Cell Therapy manufacturing cost, industry chain structure and pricing analysis are conducted. The pandemic impact in terms of production, demand, profit, growth scope is covered in our latest report updated in June 2020.

Browse More Details Or Receive Free Sample Copy With Graphs & Charts: https://www.reportscheck.com/shop/2021-2026-report-on-global-stem-cell-therapy-market-by-player-region-type-application-and-sales-channel/

The Stem Cell Therapy production, market performance over past and present years, opportunity mapping, investment feasibility and growth orbits are specified in this research report. The regional markets share of every industry player, product type and application is studied which is as follows:

Top Companies Involved in Stem Cell Therapy Industry are:Osiris TherapeuticsNuVasiveChiesi PharmaceuticalsJCRPharmaceuticalPharmicellMedi-postAnterogenMolmedTakeda (TiGenix)

Top Product Types Evaluated are:AutologousAllogeneic

Top Applications studied are:Musculoskeletal DisorderWounds & InjuriesCorneaCardiovascular DiseasesOthers

To derive the vital Stem Cell Therapy Industry aspects like market share, revenue, production, demand various primary interviews and interactions are carried out with industry experts like VPs, CEOs, Marketing Managers, R&D Managers, distributors, national sales mangers of top companies. Primary and performance analysis is carried out by interviewing the distributors, traders, dealers and more. The most crucial segment like Stem Cell Therapy Market competition and trends is studied in this report.

Ask Any Query, Request Custom Information or View Report TOC: https://www.reportscheck.com/shop/2021-2026-report-on-global-stem-cell-therapy-market-by-player-region-type-application-and-sales-channel/

The report evaluates the positive and negative impact of ongoing situations on Stem Cell Therapy Industry with forecast opportunities and CAGR value. The historical and present industry situations, market trends, technological innovations, regulations, upcoming technologies, and challenges are covered. The Stem Cell Therapy Market revenue is expected to surpass US$ XX Million by 2021 with a growth rate of xx.xx% from 2021-2027.

Regional Perspective and Stem Cell Therapy Analysis:

The market scope and regional division include North America, Europe, Asia-Pacific, Middle East & Africa, South America, and Rest of the World. The industry presence in the Asia-Pacific region is expected to expand at a good pace due to the increase in production facilities, existing players developing new opportunities and new players emerging in Stem Cell Therapy Market. North America is expected to reach a higher market share followed by the European region. Demand for Stem Cell Therapy products and its relevant applications across different market segments is growing rapidly.

Stem Cell Therapy Market Analysis Based on Top Companies:

After the market competition and overview by top players, company profiles of every Stem Cell Therapy Industry player is provided in detail. This segment covers the company overview, business portfolio, production details & description, vital financials, developments, SWOT analysis, and more. Top companies across the globe are profiled in this research study. The report can be customized based on the users choice and more players can be added as per requirements.

The forecast Stem Cell Therapy industry vision covers the market size estimation, growth driving factors, risk analysis & mitigation, new entrants SWOT analysis, and investment feasibility.

Key Assessments & Stem Cell Therapy Market Research Report Highlights:

Thanks for reading our article. For any queries, questions, or custom requirements feel free to reach us or contact our analyst. We offer the report as per the clients stated scenario.

Contact Us:

Olivia Martin

Marketing Manager

Email: [emailprotected]

Website:www.reportscheck.com

Original post:

Tag: Stem Cell Therapy Growth - Cole of Duty

A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report -…

This article was originally published here

Stem Cell Res Ther. 2020 Jul 16;11(1):291. doi: 10.1186/s13287-020-01802-8.

ABSTRACT

Acute respiratory distress syndrome virus-2 (SARS-CoV-2) responsible for coronavirus disease 2019 (COVID-19) infection, which causes global public health emergencies, has sped widely for more than 5 months and has the risk of long-term transmission. No effective treatment has been discovered to date. In the cases we report, the patient continued to deteriorate even after administration of antiviral drugs such as lopinavir/ritonavir, interferon-, and ribavirin, as well as intravenous injection of meropenem, methylprednisolone, and immunoglobulin. So, we infused the patient with convalescent plasma (CP), and the absolute lymphocyte count increased the next day and returned to normal on the fourth day. Followed by intravenous infusion of mesenchymal stem cells (MSCs), bilateral infiltrates were absorbed and the pulmonary function was significantly improved. We note that the intravenous infusion of CP and MSCs for the treatment of severe COVID-19 patients may have synergistic characteristics in inhibiting cytokine storm, promoting the repair of lung injury, and recovering pulmonary function. We hope to provide a reference for the research direction of COVID-19 clinical strategies.

PMID:32678017 | DOI:10.1186/s13287-020-01802-8

Visit link:

A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report -...


...7891011...203040...